# US 2026/0028611 A1 · Metabolic selection via asparagine biosynthesis pathway

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0028611 A1
- Document ID: US20260028611A1
- Status: Published application
- Kind: A1
- Application number: 18/842,333
- Filed: 2023-03-03
- Published: 2026-01-29
- Earliest claimed: 2022-03-04
- Assignees: Sigma-Aldrich Co.
- Applicants: Sigma-Aldrich Co. LLC
- Inventors: James Ravellette; Mary Otto; David Razafsky; Jason A. Gustin; Trissa Borgschulte
- Web page: https://patentgrep.com/patent/US20260028611A1

## CPC

- C12N 9/93: {Ligases (6)}
- C12N 15/85: for animal cells
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- C12Y 603/01002: Glutamate-ammonia ligase (6.3.1.2)
- C12Y 603/05004: Asparagine synthase (glutamine-hydrolyzing) (6.3.5.4)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12Y: ENZYMES

## Abstract

The present disclosure provides an isolated mammalian cell comprising a reduced or eliminated expression of Asparagine Synthetase (ASNS). Further provided are methods for preparing such cells and methods for using such cells for the production of recombinant proteins.

## Claims

### Claim 1

A method for producing a recombinant protein product, the process comprising
(a) providing a mammalian cell line engineered to have reduced or eliminated expression of endogenous asparagine synthetase (ASNS);
(b) introducing into the mammalian cell line a polynucleotide, wherein the polynucleotide encodes a functional ASNS gene and the recombinant protein;
(c) culturing the cell line; and
(d) purifying the recombinant protein to form the recombinant protein product.

### Claim 2 (depends on 1)

The method of claim 1, wherein the mammalian cell line of (a) further comprises reduced or eliminated expression of endogenous glutamine synthetase (GS).

### Claim 3 (depends on 1)

The method of claim 1, wherein the endogenous ASNS expression is reduced or eliminated by inactivating the endogenous ASNS gene of the mammalian cell line.

### Claim 4 (depends on 1)

The method of claim 1, wherein the endogenous ASNS gene is inactivated using a targeting endonuclease-mediated genome modification technique.

### Claim 5 (depends on 4)

The method of claim 4, wherein the targeting endonuclease is a CRISPR ribonucleoprotein complex or a pair of zinc finger nucleases.

### Claim 6 (depends on 1)

The method of claim 1, wherein the mammalian cell line is a Chinese hamster ovary (CHO) cell line, a baby hamster kidney (BHK) cell line, a NS0 mouse myeloma cell line, a HEK293 cell line, or a Vero African green monkey kidney cell line.

### Claim 7 (depends on 1)

The method of claim 1, wherein the cell line is a CHO cell line.

### Claim 8 (depends on 1)

The method of claim 1, wherein the recombinant protein product is chosen from an antibody, an antibody fragment, a vaccine, a growth factor, a cytokine, a hormone, or a clotting factor.

### Claim 9 (depends on 8)

The method of claim 8, wherein the antibody is a bispecific or multispecific antibody.

### Claim 10

A genetically engineered mammalian cell line for use in a biologic production system, wherein the mammalian cell line is engineered to have reduced or eliminated expression of endogenous ASNS.

### Claim 11 (depends on 10)

The mammalian cell line of claim 10, wherein expression of ASNS is reduced or eliminated via inactivation of at least one allele of a chromosomal sequence encoding ASNS.

### Claim 12

(canceled)

### Claim 13 (depends on 10)

The mammalian cell line of claim 10, wherein the cell line is engineered to have reduced or eliminated expression of endogenous glutamine synthetase (GS).

### Claim 14 (depends on 11)

The mammalian cell line of claim 11, wherein the chromosomal sequence is inactivated using a targeting endonuclease-mediated genome modification technique.

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17 (depends on 14)

The mammalian cell line of claim 14 wherein the cell line is a CHO cell line.

### Claim 18

(canceled)

### Claim 19 (depends on 10)

The mammalian cell line of claim 10, further comprising at least one nucleic acid encoding a recombinant protein chosen from an antibody, an antibody fragment, a vaccine, a growth factor, a cytokine, a hormone, or a clotting factor.

### Claim 20 (depends on 19)

The mammalian cell line of claim 19, wherein the antibody is a bispecific or multispecific antibody.

### Claim 21

A polynucleotide comprising a nucleic acid sequence encoding a functional ASNS and at least one recombinant protein of interest.

### Claim 22 (depends on 1)

A polynucleotide comprising
a) a nucleic acid sequence encoding a functional ASNS;
b) a nucleic acid sequence encoding a functional GS; and
c) a nucleic acid sequence encoding a recombinant protein of interest. The method of claim 1, wherein the functional ASNS gene comprises a heterologous promoter sequence.

### Claim 23 (depends on 1)

The method of claim 1, wherein the functional ASNS gene comprises an endogenous promoter sequence.

### Claim 24 (depends on 23)

The method of claim 23, wherein the endogenous promoter is the endogenous ASNS promoter.

### Claim 25

(canceled)
